PriceTargets.com logo

Serina Therapeutics - SER Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.94 As of 06/30/2026 05:10 PM ET
▼ -0.03 (-1.52%)

This chart shows the closing price for SER by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Serina Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SER

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Serina Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.94.

This chart shows the closing price for SER for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Serina Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/1/2026BTIG ResearchInitiated CoverageBuy$8.00
(Data available from 7/1/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2026
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2026
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2026

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Serina Therapeutics logo
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Read More

Today's Range

Now: $1.94
Low: $1.86
High: $1.97

50 Day Range

MA: $1.85
Low: $1.51
High: $2.10

52 Week Range

Now: $1.94
Low: $1.22
High: $7.92

Volume

40,384 shs

Average Volume

136,776 shs

Market Capitalization

$29.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Serina Therapeutics?

The following sell-side analysts have issued reports on Serina Therapeutics in the last twelve months: BTIG Research.
View the latest analyst ratings for SER.

What is the current price target for Serina Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Serina Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Serina Therapeutics in the next year.
View the latest price targets for SER.

What is the current consensus analyst rating for Serina Therapeutics?

Serina Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SER will outperform the market and that investors should add to their positions of Serina Therapeutics.
View the latest ratings for SER.

What other companies compete with Serina Therapeutics?

Other companies that are similar to Serina Therapeutics include enGene, Cue Biopharma, Polaryx Therapeutics, Oncolytics Biotech and FitLife Brands. Learn More about companies similar to Serina Therapeutics.

How do I contact Serina Therapeutics' investor relations team?

Serina Therapeutics' physical mailing address is 601 GENOME WAY, SUITE 2001, HUNTSVILLE, AL, 35806. The company's listed phone number is (256) 327-9630. The official website for Serina Therapeutics is serinatherapeutics.com. Learn More about contacing Serina Therapeutics investor relations.